AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30514660 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 207
Study 29470530 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention regarding tuberculosis using the developed module
Number of subjects: 226
Study 29470530 — intervention group
Group type: COMPARATOR
Intervention: Normal services provided for HIV patients
Number of subjects: 226
Study 27694262 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 165
Study 27694262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 24861826 — intervention group
Group type: EXPERIMENTAL
Intervention: 5° lateral wedge insoles
Number of subjects: 8
Study 24861826 — intervention group
Group type: COMPARATOR
Intervention: Control (standard shoe)
Number of subjects: 8
Study 22332908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg trans-resveratrol twice daily for 12 weeks
Number of subjects: 39
Study 22332908 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg trans-resveratrol twice daily for 12 weeks
Number of subjects: 39
Study 22332908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20163869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters
Number of subjects: 186
Study 20163869 — intervention group
Group type: COMPARATOR
Intervention: Patching
Number of subjects: 186
Study 17581311 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet
Number of subjects: 42
Study 17581311 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet plus aerobic exercise
Number of subjects: 42
Study 17581311 — intervention group
Group type: COMPARATOR
Intervention: Control (diet only)
Number of subjects: 42
Study 17581311 — intervention group
Group type: COMPARATOR
Intervention: Control (diet plus exercise)
Number of subjects: 42
Study 15800296 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 509
Study 12118024 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 400
Study 12118024 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 400
Study 10205954 — intervention group
Group type: EXPERIMENTAL
Intervention: NMAB‐urea
Number of subjects: 150
Study 10205954 — intervention group
Group type: EXPERIMENTAL
Intervention: NMAB
Number of subjects: 150
Study 10205954 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 150
Study 7792498 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 10
Study 7792498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10
Study 7792498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2145874 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69,578 (atriopeptidase inhibitor) administered as an intravenous infusion over 20 min
Number of subjects: 6
Study 2145874 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69,578 (atriopeptidase inhibitor)
Number of subjects: 6
Study 2145874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 620911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (0.8 to 1.2 g daily for 2 to 6 weeks)
Number of subjects: 0
Study 620911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 620911 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization (2 to 3 weeks)
Number of subjects: 0
Study 620911 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine therapy cessation
Number of subjects: 0
Study 620911 — intervention group
Group type: COMPARATOR
Intervention: Chronic or intermittent cimetidine therapy
Number of subjects: 0
Study 30957985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=59)
Number of subjects: 122
Study 30957985 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=63)
Number of subjects: 122
Study 30347090 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized weaning via early extubation to noninvasive ventilation (n=182)
Number of subjects: 364
Study 30347090 — intervention group
Group type: COMPARATOR
Intervention: Protocolized standard weaning (continued invasive ventilation until successful spontaneous breathing trial, followed by extubation) (n=182)
Number of subjects: 364
Study 30347090 — intervention group
Group type: COMPARATOR
Intervention: Protocolized standard weaning (n=182)
Number of subjects: 364
Study 27803139 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 60
Study 27803139 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 60
Study 27803139 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors (Infliximab and Etanercept)
Number of subjects: 60
Study 24673513 — intervention group
Group type: EXPERIMENTAL
Intervention: Benvitimod (0.5-2.0%) cream, doses escalated from 5 to 30 mg daily, applied once or twice daily
Number of subjects: 56
Study 24673513 — intervention group
Group type: EXPERIMENTAL
Intervention: Benvitimod (5 mg q.d and b.i.d)
Number of subjects: 56
Study 24673513 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 56
Study 22988684 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office treatment with desensitizing paste containing 8% arginine and calcium carbonate, followed by brushing with desensitizing toothpaste containing 8% arginine, calcium carbonate with 1450 ppm fluoride for 24 weeks.
Number of subjects: 100
Study 22988684 — intervention group
Group type: COMPARATOR
Intervention: Nupro-M pumice prophylaxis paste, followed by brushing with non-desensitizing toothpaste containing 1450 ppm fluoride for 24 weeks.
Number of subjects: 100
Study 20174763 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 10735
Study 20174763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10735
Study 20174763 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide
Number of subjects: 10735
Study 20174763 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet treatment (overall)
Number of subjects: 10735
Study 17431110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonafarnib (Farnesyl transferase inhibitor)
Number of subjects: 0
Study 15867580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA MMx (1.2 g three times per day)
Number of subjects: 79
Study 15867580 — intervention group
Group type: COMPARATOR
Intervention: 5‐ASA enema (4 g)
Number of subjects: 79
Study 15867580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA MMx
Number of subjects: 79
Study 15867580 — intervention group
Group type: COMPARATOR
Intervention: 5‐ASA enema
Number of subjects: 79
Study 16679206 — intervention group
Group type: EXPERIMENTAL
Intervention: Long buccal-segment group (canines, both premolars, and first molars)
Number of subjects: 20
Study 16679206 — intervention group
Group type: EXPERIMENTAL
Intervention: Short buccal-segment group (only maxillary first molars)
Number of subjects: 20
Study 16679206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 10826565 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Number of subjects: 7
Study 10826565 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Number of subjects: 7
Study 8858747 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (5 g/day)
Number of subjects: 204
Study 8858747 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced diet (84 g/day)
Number of subjects: 204
Study 8858747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 1515637 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu GM‐CSF (250 micrograms/m2)
Number of subjects: 91
Study 1515637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 6507509 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics continued throughout pregnancy
Number of subjects: 20
Study 6507509 — intervention group
Group type: COMPARATOR
Intervention: Diuretics discontinued immediately
Number of subjects: 20
Study 6507509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30389202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition readiness for talking with providers
Number of subjects: 251
Study 30138016 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAT intervention (15-min brief motivational interviewing)
Number of subjects: 294
Study 30138016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 294
Study 27463412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose skimmed milk enriched with 40 mg/100 mL of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), 0.54 g/100 mL oleic acid, and vitamins (n = 63)
Number of subjects: 117
Study 27463412 — intervention group
Group type: COMPARATOR
Intervention: Semiskimmed milk enriched with vitamins A and D (n = 54)
Number of subjects: 117
Study 25373811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 41
Study 25373811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22674807 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide during induction, between transplantations, and during consolidation and maintenance (TT2)
Number of subjects: 0
Study 22674807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, dexamethasone (VTD) during the first year of maintenance and thalidomide, dexamethasone (TD) for 2 more years (TT3A)
Number of subjects: 0
Study 22674807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, dexamethasone (VRD) maintenance for 3 years (TT3B)
Number of subjects: 0
Study 22674807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thalidomide) in TT2
Number of subjects: 0
Study 19609570 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (home-based aerobic and light resistance training program, weekly group sessions)
Number of subjects: 100
Study 19609570 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 19609570 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 100
Study 18756746 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural resonance electromagnetic therapy (SREMT) in the basic group
Number of subjects: 120
Study 18756746 — intervention group
Group type: COMPARATOR
Intervention: Standard drug and physiotherapeutic treatment
Number of subjects: 120
Study 15925962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 53
Study 15925962 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 53
Study 15925962 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine and Oral methadone
Number of subjects: 53
Study 12872590 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (100 mJ/pulse and 10 Hz)
Number of subjects: 2
Study 12872590 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated implants)
Number of subjects: 2
Study 10561978 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol and ketamine (n = 28)
Number of subjects: 58
Study 10561978 — intervention group
Group type: COMPARATOR
Intervention: EIGA with isoflurane (n = 30)
Number of subjects: 58
Study 8920391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 0
Study 1906441 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose TRH therapy
Number of subjects: 30
Study 30902753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) 2 h preoperatively
Number of subjects: 151
Study 30902753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) 4 h postoperatively
Number of subjects: 151
Study 30902753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) at 4, 10, and 16 h postoperatively
Number of subjects: 151
Study 28532137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 60
Study 28532137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 60
Study 25784174 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 179
Study 25784174 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 179
Study 23260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.3 mg
Number of subjects: 789
Study 23260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.5 mg
Number of subjects: 789
Study 23260261 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 789
Study 23260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ)
Number of subjects: 789
Study 23260261 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to 0.5 mg RBZ from sham at month 6
Number of subjects: 789
Study 21800642 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - 6 phone calls from a nurse specialized in tobacco cessation counselling
Number of subjects: 40
Study 21800642 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 40
Study 18771521 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (n = 14)
Number of subjects: 26
Study 18771521 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n = 12)
Number of subjects: 26
Study 18771521 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 26
Study 18771521 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 26
Study 17644340 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated phytosterol esters (2.6 g for 12 weeks)
Number of subjects: 54
Study 17644340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15486748 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol solution
Number of subjects: 33
Study 15486748 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study 11562614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 11562614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin for inhalation
Number of subjects: 246
Study 11233386 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS
Number of subjects: 119
Study 11233386 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 119
Study 8163364 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm TTS 50 patches
Number of subjects: 20
Study 8163364 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 2964845 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 50
Study 2964845 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 50
Study 2964845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Omnipaque and Gastrografin
Number of subjects: 50
Study 2964845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric follow‐through procedures
Number of subjects: 50
Study 31342199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanistic model of the immune response with T-regulatory (Treg) cell mediated tolerance adjustment
Number of subjects: 0
Study 31342199 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg-adjusted model
Number of subjects: 0
Study 28882773 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT) plus specific exercise programme
Number of subjects: 42
Study 28882773 — intervention group
Group type: COMPARATOR
Intervention: Exercise programme alone
Number of subjects: 42
Study 25424501 — intervention group
Group type: EXPERIMENTAL
Intervention: FL3X behavioural intervention (minimum three sessions)
Number of subjects: 61
Study 25424501 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study 24241957 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing by trained lay counsellors using rapid tests (SD Bioline and Sensa)
Number of subjects: 3986
Study 24241957 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based ELISA testing as the gold standard
Number of subjects: 3986
Study 20673296 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial implant-supported prosthesis
Number of subjects: 189
Study 20673296 — intervention group
Group type: COMPARATOR
Intervention: No implants (control group)
Number of subjects: 189
Study 19262561 — intervention group
Group type: COMPARATOR
Intervention: Caltrate D (1 pill daily)
Number of subjects: 150
Study 16412224 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 16412224 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients
Number of subjects: 0
Study 16412224 — intervention group
Group type: COMPARATOR
Intervention: Epicardial fat
Number of subjects: 0
Study 15319704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (1.45 mg/d mean dosage)
Number of subjects: 11
Study 15319704 — intervention group
Group type: COMPARATOR
Intervention: Levodopa sustained release (190 mg/d mean dosage)
Number of subjects: 11
Study 11167169 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion with fentanyl (19.2+/‐5.2 microg x h(‐1))
Number of subjects: 20
Study 11167169 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion without fentanyl
Number of subjects: 20
Study 9024025 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands + 2 mL IV saline
Number of subjects: 75
Study 9024025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IV metoclopramide + placebo wrist bands
Number of subjects: 75
Study 9024025 — intervention group
Group type: COMPARATOR
Intervention: Placebo wrist bands + 2 mL IV saline
Number of subjects: 75
Study 8275615 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (256U87) at doses from 100 to 1000 mg (single-dose study)
Number of subjects: 12
Study 8275615 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (256U87) at doses from 250 to 2000 mg (multiple-dose study)
Number of subjects: 12
Study 8275615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3546605 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) therapy
Number of subjects: 10
Study 31536384 — intervention group
Group type: EXPERIMENTAL
Intervention: Games-on (access to mobile games)
Number of subjects: 30
Study 31536384 — intervention group
Group type: COMPARATOR
Intervention: Games-off (no access to mobile games)
Number of subjects: 30
Study 30655665 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 µg
Number of subjects: 0
Study 30655665 — intervention group
Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 0
Study 30655665 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 28622815 — intervention group
Group type: COMPARATOR
Intervention: Computer-delivered brief intervention (CBI)
Number of subjects: 659
Study 28622815 — intervention group
Group type: COMPARATOR
Intervention: Therapist-delivered brief intervention (TBI)
Number of subjects: 659
Study 28622815 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 659
Study 25584002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy/GVAX followed by CRS-207 (arm A)
Number of subjects: 90
Study 25584002 — intervention group
Group type: COMPARATOR
Intervention: Cy/GVAX (arm B)
Number of subjects: 90
Study 23473238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal coma stimulation 5-times a day (20 minutes each session)
Number of subjects: 30
Study 23473238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal coma stimulation twice a day (50 minutes each session)
Number of subjects: 30
Study 23473238 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy twice daily
Number of subjects: 30
Study 21523806 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SCD
Number of subjects: 100
Study 21523806 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SCD and cerebral infarct
Number of subjects: 100
Study 21523806 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SCD and acute brain ischemia
Number of subjects: 100
Study 19759428 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (YG; n=62)
Number of subjects: 291
Study 19759428 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL; n=56)
Number of subjects: 291
Study 16935774 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors
Number of subjects: 0
Study 16935774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 0
Study 16935774 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors plus aromatase inhibitors
Number of subjects: 0
Study 16935774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicer downregulation
Number of subjects: 0
Study 16935774 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Wnt genes and methylation of Wnt antagonists
Number of subjects: 0
Study 15823768 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin during second and third treatment periods
Number of subjects: 50
Study 15823768 — intervention group
Group type: COMPARATOR
Intervention: No escin (Control) during first and fourth treatment periods
Number of subjects: 50
Study 15823768 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin treatment
Number of subjects: 50
Study 11486242 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen continuous combined HRT
Number of subjects: 74
Study 11486242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9647368 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg)
Number of subjects: 123
Study 9647368 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 123
Study 8076565 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy experience questionnaire (31-item, rated on a seven-point scale)
Number of subjects: 130